Replimune's RP1 Faces Second FDA Rejection
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy REPL?
Source: seekingalpha
- FDA Decision Impact: The U.S. FDA's second rejection of Replimune's RP1 Biologics License Application indicates insufficient data demonstrating the drug's efficacy for unresectable advanced cutaneous melanoma, potentially leading to increased market risk and diminished investor confidence.
- Application Context: RP1 was intended for use in combination with Bristol Myers' Opdivo (nivolumab) for advanced melanoma patients who had previously undergone anti-PD-1 treatments; however, the FDA's complete response letter highlights a lack of supporting data for its combination therapy, affecting future market prospects.
- Market Reaction: Prior to the trading halt, Replimune's shares plummeted, reflecting strong investor reactions to the FDA's rejection, which may pose greater challenges for the company in future financing and research endeavors.
- Future Outlook: Although the FDA's decision delays RP1's approval timeline to April 2026, the company must reassess its clinical data and market strategy to enhance the likelihood of future application success and restore investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REPL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REPL
Wall Street analysts forecast REPL stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 5.910
Low
3.00
Averages
11.43
High
18.00
Current: 5.910
Low
3.00
Averages
11.43
High
18.00
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
REPLIMUNE INITIATES IGNYTE-3 IN RESPONSE TO FDA INPUT TO MEET REGULATORY REQUIREMENT FOR CONFIRMATORY STUDY IN ACCELERATED APPROVAL PROCESS
Regulatory Requirement: A new regulatory requirement has been initiated that mandates a confirmatory study to be conducted for the approval process.
Accelerated Approval: The study is aimed at facilitating an accelerated approval pathway for a product or treatment.
See More
REPLIMUNE GROUP: DISPUTES FDA'S VIEW ON ADEQUACY OF RP1 BLA DATA FOR ADVANCED CANCER PATIENT ACCESS
Disagreement on Data Sufficiency: Replimune Group disagrees with the FDA regarding the adequacy of the RP1 Bladataset for allowing the medicine to be made available to advanced cancer patients.
Impact on Advanced Cancer Patients: The disagreement may affect the availability of a potentially beneficial treatment for patients with advanced cancer.
See More
FDA's Complete Response Letter: Insufficient Data to Support Effectiveness of Replimune's Vusolimogene Oderparepvec
Insufficient Data: The FDA's response letter indicates that the data provided was not enough to conclude the effectiveness of Repliclimun's Vusolimogene therapy.
Lack of Substantial Evidence: The letter emphasizes that there is no substantial evidence supporting the claims of effectiveness for the treatment in question.
See More
Replimune Cuts Workforce After FDA Rejects RP1 Approval
- FDA Rejection: Replimune's lead asset RP1 was denied FDA approval, forcing the company to reduce its workforce and scale back U.S. manufacturing operations, highlighting the significant impact of regulatory environments on biotech firms.
- Stock Plunge: Following a trading halt, Replimune's stock plummeted approximately 63% in after-hours trading, reflecting the market's strong reaction to the FDA's rejection and a pessimistic outlook on the company's future.
- CEO's Disappointment: CEO Sushil Patel expressed disappointment over the FDA's decision, arguing that it contradicted prior communications from the agency and emphasized the urgent need for patients to access the treatment.
- Unmet Treatment Needs: The rejection of RP1, intended as a second-line therapy for advanced melanoma, means patients will continue to lack effective treatment options, underscoring the challenges faced by the biopharmaceutical industry.
See More
IOVA Benefits from Rival Drug Rejection, Analysts Bullish
- FDA Drug Rejection Impact: The FDA's rejection of Replimune's RP1 due to insufficient data is viewed positively for Iovance's Amtagvi, enhancing its competitive position in the near term and potentially increasing market share.
- Sales Growth Expectations: Iovance's Amtagvi is projected to generate approximately $220 million in revenue for 2025, with analysts highlighting that sales acceleration and margin expansion will be central to the company's future growth.
- Market Reaction Analysis: Despite the FDA rejection being seen as a positive development, IOVA's stock fell 8%, surprising retail investors and indicating the complexity of market sentiment surrounding the stock.
- Analyst Ratings Optimistic: Among 11 analysts, 8 have rated IOVA as a 'Buy', with an average 12-month price target of $9, representing a potential upside of about 144%, reflecting strong confidence in its future performance.
See More
Replimune Faces FDA Rejection for RP1 Application
- FDA Rejection Letter: Replimune received a complete response letter from the FDA rejecting its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma, indicating a disagreement over the sufficiency of the data set, which could impact the company's future financing and R&D plans.
- Clinical Trial Results: In the IGNYTE trial, patients treated with RP1 plus nivolumab had a 34% response rate with a median duration of 24.8 months, yet despite the supportive data, the FDA's refusal for accelerated approval forces the company to consider layoffs and scale back U.S. manufacturing operations.
- Regulatory Communication Issues: The new review team did not engage effectively with Replimune, despite the company providing additional supportive data, and the FDA's stance contradicted previous meeting records, highlighting fragmentation and inconsistency in the regulatory process that may hinder innovation.
- Melanoma Landscape: With an estimated 112,000 new melanoma cases in the U.S. in 2026 and approximately 8,500 deaths annually, the failure to approve RP1 as a novel treatment option leaves patients with fewer choices, exacerbating the gap between medical needs and available therapies.
See More
REPLIMUNE INITIATES IGNYTE-3 IN RESPONSE TO FDA INPUT TO MEET REGULATORY REQUIREMENT FOR CONFIRMATORY STUDY IN ACCELERATED APPROVAL PROCESS
Regulatory Requirement: A new regulatory requirement has been initiated that mandates a confirmatory study to be conducted for the approval process.
Accelerated Approval: The study is aimed at facilitating an accelerated approval pathway for a product or treatment.
See More
REPLIMUNE GROUP: DISPUTES FDA'S VIEW ON ADEQUACY OF RP1 BLA DATA FOR ADVANCED CANCER PATIENT ACCESS
Disagreement on Data Sufficiency: Replimune Group disagrees with the FDA regarding the adequacy of the RP1 Bladataset for allowing the medicine to be made available to advanced cancer patients.
Impact on Advanced Cancer Patients: The disagreement may affect the availability of a potentially beneficial treatment for patients with advanced cancer.
See More
FDA's Complete Response Letter: Insufficient Data to Support Effectiveness of Replimune's Vusolimogene Oderparepvec
Insufficient Data: The FDA's response letter indicates that the data provided was not enough to conclude the effectiveness of Repliclimun's Vusolimogene therapy.
Lack of Substantial Evidence: The letter emphasizes that there is no substantial evidence supporting the claims of effectiveness for the treatment in question.
See More
Replimune Cuts Workforce After FDA Rejects RP1 Approval
- FDA Rejection: Replimune's lead asset RP1 was denied FDA approval, forcing the company to reduce its workforce and scale back U.S. manufacturing operations, highlighting the significant impact of regulatory environments on biotech firms.
- Stock Plunge: Following a trading halt, Replimune's stock plummeted approximately 63% in after-hours trading, reflecting the market's strong reaction to the FDA's rejection and a pessimistic outlook on the company's future.
- CEO's Disappointment: CEO Sushil Patel expressed disappointment over the FDA's decision, arguing that it contradicted prior communications from the agency and emphasized the urgent need for patients to access the treatment.
- Unmet Treatment Needs: The rejection of RP1, intended as a second-line therapy for advanced melanoma, means patients will continue to lack effective treatment options, underscoring the challenges faced by the biopharmaceutical industry.
See More
IOVA Benefits from Rival Drug Rejection, Analysts Bullish
- FDA Drug Rejection Impact: The FDA's rejection of Replimune's RP1 due to insufficient data is viewed positively for Iovance's Amtagvi, enhancing its competitive position in the near term and potentially increasing market share.
- Sales Growth Expectations: Iovance's Amtagvi is projected to generate approximately $220 million in revenue for 2025, with analysts highlighting that sales acceleration and margin expansion will be central to the company's future growth.
- Market Reaction Analysis: Despite the FDA rejection being seen as a positive development, IOVA's stock fell 8%, surprising retail investors and indicating the complexity of market sentiment surrounding the stock.
- Analyst Ratings Optimistic: Among 11 analysts, 8 have rated IOVA as a 'Buy', with an average 12-month price target of $9, representing a potential upside of about 144%, reflecting strong confidence in its future performance.
See More
Replimune Faces FDA Rejection for RP1 Application
- FDA Rejection Letter: Replimune received a complete response letter from the FDA rejecting its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma, indicating a disagreement over the sufficiency of the data set, which could impact the company's future financing and R&D plans.
- Clinical Trial Results: In the IGNYTE trial, patients treated with RP1 plus nivolumab had a 34% response rate with a median duration of 24.8 months, yet despite the supportive data, the FDA's refusal for accelerated approval forces the company to consider layoffs and scale back U.S. manufacturing operations.
- Regulatory Communication Issues: The new review team did not engage effectively with Replimune, despite the company providing additional supportive data, and the FDA's stance contradicted previous meeting records, highlighting fragmentation and inconsistency in the regulatory process that may hinder innovation.
- Melanoma Landscape: With an estimated 112,000 new melanoma cases in the U.S. in 2026 and approximately 8,500 deaths annually, the failure to approve RP1 as a novel treatment option leaves patients with fewer choices, exacerbating the gap between medical needs and available therapies.
See More
